Additional contributions to the field include studies suggesting that the PI3K/AKT pathway is upregulated in FGFR inhibitor-resistant non-ICC models, which may be overcome by co-targeting with an mTOR inhibitor19. This evidence concerns the gene AKT1 and intrahepatic cholangiocarcinoma.